MedTrace Logo

A Study to Observe Real-life Allocation of Antipsychotics in Acute Inpatient Management of Schizophrenia

NCT01394601 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2012-11-05

No results posted yet for this study

Summary

RECONNECT-S ALPHA is a multicentre study to observe the management of schizophrenic patients who are hospitalized due to an acutely agitated psychotic episode. The patients should be managed according to normal clinical practice until discharge time. Data will be collected by review of medical records of the hospitalisation prior the study visit. During the study the patients will conduct one visit on the day of their discharge after hospitalisation due to an acutely agitated psychotic episode. On the study visit data on demographics, diagnosis and medical history will be recorded. Data on antipsychotic and concomitant medication will be collected by review of medical records.

Conditions

Sponsors & Collaborators

Principal Investigators

  • Alexey Stepanov · AstraZeneca

  • Nikolay Govorin · Chita State Medical Akademy of Roszdraw

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01394601 on ClinicalTrials.gov